The Office of Research Regulatory Affairs team offers complete regulatory support for investigator-initiated drug or device studies. UAMS acts as the sponsor for all Investigational New Drug applications and Investigational Device Exemptions filed on behalf of our investigators. The group provides a number of support services including regulatory evaluation, quality assurance compliance, monitoring, good tissue practice, and clinical trials registration. The Office of Research Regulatory Regulatory Affairs, in concert with other UAMS regulatory compliance departments, ensures that Investigational New Drug application (IND) and Investigational Device Exemption (IDE) studies remain in compliance as required under Title 21 of the Code of Federal Regulations.
The Regulatory Unit, in accordance with applicable regulations, will review your study to determine the need for an Investigational New Drug application or an Investigational Device Exemption (IDE). If an Investigational New Drug application or Investigational Device Exemption is required, we work with the Principal Investigator and their staff to compile, build, file, and manage the Investigational New Drug application / Investigational Device Exemption study. We also provide assistance with orphan drug applications and submissions, compassionate use drug or device requests, and Food and Drug Administration Pre-Investigational New Drug application / Investigational Device Exemption meetings.
Monitors are responsible for monitoring all UAMS-sponsored investigator-initiated Investigational New Drug application / Investigational Device Exemption research studies. In addition to conducting periodic monitoring visits throughout the course of your study, we can provide assistance with the preparation of essential study documents (regulatory binders, source documentation, case report forms, etc.). We conduct the required site initiation visits, closeout visits, and can assist with audit preparations. The monitoring team aims to ensure quality data collection, adherence with the investigational plan, and compliance with applicable regulations.
The quality oversight of non-research activities is provided as a result of quality program mandates under the FDA Good Tissue Practices (GTP) regulations finalized May 25, 2005. These regulations give the agency more authority and oversight over a broader range of tissues and the establishments that process them. Our Good Tissue Practices specialist accomplishes its mission through quality assurance and control functions including, but not limited to, education, training, auditing, inspecting, and establishing appropriate procedures.
Quality Assurance has the mission of maintaining UAMS compliance with all federal, state, and local regulations governing the manufacturing of human cells, tissues, and cellular and tissue-based products (HCT/P’s).
Contact the Regulatory Affairs team at RegulatoryAffairs@uams.edu.